- NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company, closed a $42M funding round
- The round was led by BioTrack Capital and Yonghua Capital with participation from Taifu Capital, Panlin Capital, Juming Capital, and Tuobang Capital and previous investors
- The company also intends to use the funds to expand the commercial team in both the US and China, develop new NGS products
- NuProbe is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations
- In the past 12 months, NuProbe has signed a number of partnership and licensing deals with internationally renowned companies in molecular diagnostics and life sciences
- Then the company has begun to partner with pharma companies for clinical research through its Augury™ custom NGS panels
